User:Mr. Ibrahem/Ocrelizumab

Ocrelizumab, sold under the brand name Ocrevus, is a medication used to treat multiple sclerosis (MS). Specifically it is used for relapsing MS (RMS) and primary progressive MS (PPMS). It is given by gradual injection into a vein.

Common side effects include rash, itching, trouble breathing, and infection. Other side effects may include cancer. Safety in pregnancy is unclear. It is a monoclonal antibody that binds to CD20 on B lymphocytes reducing their activity.

Ocrelizumab was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom it costs the NHS about £4,800 per 300 mg as of 2021. In the United States this amount costs about 18,000 USD.